阿托品与安慰剂在新生儿非紧急插管中的随机临床试验
这项多中心双盲随机临床试验比较了新生儿非紧急经口气管插管前使用阿托品-芬太尼-琥珀胆碱与安慰剂-芬太尼-琥珀胆碱对严重心动过缓的影响。结果显示,安慰剂组严重心动过缓发生率显著高于阿托品组(RR 6.3,95%CI 1.2-34.1),两组均无安全事件发生。
要点
- 插管前使用阿托品可显著降低新生儿严重心动过缓的发生率。
- 安慰剂组总体心动过缓发生率和持续时间显著更高,但低氧血症发生率更低。
- 两组均未发生严重心动过缓相关安全事件。
核心结论
- 在新生儿非紧急插管预用药中,与安慰剂相比,阿托品显著降低了严重心动过缓和总体心动过缓的发生率及持续时间。
研究设计与样本
- 多中心、双盲、随机临床试验,纳入接受非紧急插管的新生儿,按随机化时矫正胎龄(<34周和≥34周)分层,采用意向性分析。
主要发现
- 整个操作过程中严重心动过缓(<80/min持续>10秒)在安慰剂组显著高于阿托品组(RR 6.3;95%CI 1.2-34.1)。
- 两组均未发生严重心动过缓(<60/min持续>10秒)、接受胸外按压或肾上腺素等安全事件。
临床怎么用
- 对于需要非紧急插管的新生儿,可考虑在预用药方案中加入阿托品以降低严重心动过缓风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the rates of severe bradycardia (<80/min for >10 seconds) between neonates who received atropine-fentanyl-succinylcholine (atropine/standard-of-care group) vs placebo-fentanyl-succinylcholine (placebo/intervention group) before orotracheal intubation. STUDY DESIGN: A multicenter, double-blind, randomized clinical trial of neonates receiving nonemergent intubation. Randomization was by computer generated tables with random block size, stratified by postmenstrual age at randomization (<34 weeks and ≥34 weeks). The primary outcome was severe bradycardia during the whole procedure (from administration of the study medication until completion of last successful intubation). Secondary outcomes included any bradycardia (<100/min for >10 seconds), number and duration of intubation attempts and hypoxemia (<80% for >10 seconds). Safety outcomes included profound bradycardia (<60/min for >10 seconds), and receipt of chest compression or epinephrine. Analysis was by intention to treat. RESULTS: Seventy-three intubation events (60 infants) were randomized to administration of atropine (n = 24) or placebo (n = 49). Multiple attempts occurred in 33% of the events. No safety events occurred in either group. Severe bradycardia during the whole procedure was significantly higher in the placebo group compared with the atropine group (RR, 6.3; 95% CI, 1.2-34.1). The placebo group had significantly higher rates and duration of overall bradycardia, but lower rates and duration of hypoxemia compared with the atropine group, probably related to the lower proportion of multiple attempts (27% vs 46%; P = .09) and longer time to successful intubation (394 seconds vs 283 seconds; P = .08). CONCLUSIONS: Among neonates receiving premedication for nonemergent intubation, atropine significantly decreased the rates and duration of severe and overall bradycardia compared with placebo. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01595399 (https://clinicaltrials.gov/study/NCT01595399).
引用
- Afifi J, El-Naggar W, Hatfield T, et al. Atropine Versus Placebo for Neonatal Nonemergent Intubation: A Randomized Clinical Trial. J Pediatr. 2025. PMID: 40645282. doi:10.1016/j.jpeds.2025.114719
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。